- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Hikal Ltd. reported Q1 FY27 revenue of ₹403 Cr (up 6.2% YoY) and EBITDA of ₹37 Cr (up 47.4% YoY), with margins at 9.2%. The Pharma business grew 15.2% but sales were impacted by US FDA remediation efforts and plant shutdowns, now nearing completion. Crop Protection saw domestic growth in own products, though CDMO remained subdued due to inventory adjustments and rising input costs. Animal Health delivered resilient performance. A new Personal Care facility was commissioned. Management expresses confidence in a stepwise revenue and profitability recovery during FY27.